Volume 22, Number 12—December 2016
Dispatch
Evaluating Healthcare Claims for Neurocysticercosis by Using All-Payer All-Claims Data, Oregon, 2010–2013
Robert H. Flecker
, Seth E. O’Neal, and John M. Townes
, Seth E. O’Neal, and John M. Townes
Table
Diagnostic codes in healthcare claims from persons with neurocysticercosis (cases) versus age- and sex-matched controls, Oregon, 2010–2013
| Diagnostic code group | No. (%) cases, n = 125 | No. (%) controls, n = 500 | Odds ratio (95% CI) |
|---|---|---|---|
| Meningitis/encephalitis | 5 (4.0) | 1 (0.2) | 20.0 (2.3–171.2) |
| Seizure | 41 (32.8) | 19 (3.8) | 13.3 (6.8–25.9) |
| Stroke | 17 (13.6) | 16 (3.2) | 5.6 (2.5–12.4) |
| Headache | 63 (50.4) | 120 (24.0) | 3.2 (2.1–4.8) |
| Cognitive disorder | 11 (8.8) | 16 (3.2) | 3.1 (1.4–7.1) |
| Syncope | 12 (9.6) | 25 (5.0 | 2.0 (1.0–4.2) |
| Psychotic disorder | 8 (6.4) | 21 (4.2) | 1.6 (0.7–3.8) |
| Anxiety disorder | 35 (28.0) | 124 (24.8) | 1.2 (0.8–1.8) |
| Mood disorder | 32 (25.6) | 134 (26.8) | 0.9 (0.6–1.5) |
| Hydrocephalus | 7 (5.6) | 0 | * |
| Cerebral edema | 5 (4.0) | 0 | * |
*Hydrocephalus and cerebral edema were significantly more common among cases. However, the odds ratio could not be calculated because these diagnostic codes did not occur in the control group.
Page created: November 18, 2016
Page updated: November 18, 2016
Page reviewed: November 18, 2016
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.